MITRE / FLUX NOTES CONCEPTS vI7 - Labs, Clinical Trials, Derived, Med Resources
DANIEL REEVES, JUHAN SONIN, 5.Apr.2019


I ITERATIONS: LABS AND VITALS



The user hovers over an element in the picker. It highlights and exposes "hide" and "star" interactions. Starring can also be applied along the left hand side.




Starred charts are additionally shown at the top of the list in a special starred group.



The user selects a data point, thereby selecting the DATE. This displays all values for that date both on the chart itself and on a separate value list to the side of the picker.

Labs





In table mode, the time window is fixed to whatever fits in the screen, although it can still be panned left and right along the timeline. The picker is gone, and starring can still be done along the title row. Again, starred labs/vitals appear again at the top of the list (not shown).

Labs





				2017 Mar 10	Oct 22		2018 Feb 2	Feb 26	Mar 2	Mar 15	Apr 10	Apr 12
	Blood urea nitrogen	units		4	4	4	4	4	4	4	4	4
	C type lab	units		5	5	5	5	5	5	5	5	5
	D type lab	units			6	6	6		6	6	6	6
	Estrogen	units			7	7	7		7	7	7	7
	F lab	units			1	1	1		1	1	1	1
	Globuglobin	units		3	3	3	3	3	3	3	3	3
	J lab	units		4	10	4	4	4	4	4	4	4
	Ketones	units		5.2	5.2	5.2	5.2	5.2	5.2	5.2	5.2	5.2
	Lymphomes	units							3	3		
	Platelets	units							4	4		
	Qubits	units		1	1		1	1	1	1	1	1
*	Stronomyomes	units		2	2		2	2	2	2	2	2
	T							2.4				
2014	2015	1	III	2016	1	III	2017	- 1		20	1 1111	today

2 REVISIT: CLINICAL TRIALS

Clinical Trials

Enrolled (1)

Trial	Start date	End date	Description
PATINA	4 Nov 2018	4 Nov 2018	Metastatic breast cancer trial with drug XYZAB

∨ Potential to enroll (6)

Trial	Criteria missing
ABRACADABRA	2
PINTO	3
Xanpax Phase II	6
Another trial short name	7
show 2 hidden tria	als


select a trial at left to see enrollment details

Clinical Trials

Enrolled (1)			
Trial	Start date	End date	Description
PATINA	4 Nov 2018	4 Nov 2018	Metastatic breast cancer trial with drug XYZAB

Potential to enroll (6)

Trial	Criteria missing		
ABRACADABRA	2		
PINTO	3		
Xanpax Phase II	6		
Another trial short name	7		
show 2 hidden tria	als		



Clinical Trials

Enrolled (1)

Trial	Start date	End date	Description
PATINA	4 Nov 2018	4 Nov 2018	Metastatic breast cancer trial with drug XYZAB

∨ Potential to enroll (6)

Trial	Criteria missing
ABRACADABRA	2
PINTO	3
Xanpax Phase II	6
Another trial short name	7
show 2 hidden tri	als

PINTO

Primary investigation in nano-tubular oncological treatment

Subjects will be randomized into one of two treatment arms following minimum of 4 and maximum of 8 cycles of induction treatment with anti-HER2 therapy. Arm A subjects will receive the experimental th...

website start date: 5 Jun 2019

ClinicalTrials.gov enrollment end: 1 May 2019

location: Boston, MA

Confirm eligibility

The patient satisfies all criteria and is eligible.

show all 14 criteria

+ Insert enrollment in note

3 DERIVED VALUES



Debra24 Hernandez98Aj

Date of birth 5 Apr 1967 (51) Admin. sex Female

Location Boston, MA 12345432312 Language English

ROID

Condition gastrointestinal stromal tumor

Q Debra24 search...

SUMMARY RECORD


CURATE

Patient summary

Condition summary **Condition Summary** Gastrointestinal stromal tumor Diagnosis Gastrointestinal stromal tumor Name Diagnosis date Location Stomach Recurrence date Clinical status Remission Mitosis KIT exon 11 mutation+ Genomics Tumor size Biomarkers Histological grade go to disease status Disease status Clinical stage Complete response Disease status Pathological stage As of 24 Jan 2019 Lab results Rationale missing White blood cell Treatment go to medications go to procedures Neutrophil Imatinib 400mg tablet pre-adjuvent 22 Feb 2019 — Platelet count Surgery bin computed treatment type Key toxicities The medication is pre-adjuvent based on the related surgery date x remove label, "pre-adjuvent" is incorrect + insert "Imatinib 400mg tablet, pre-adjuvent" open source note

Dr. Freedom Brown 22 Feb 2019

25 Dec 2016 N/A 20 per 50 HPF 8 cm 2 (moderately differentiated) IIIAmissing go to lab results $(10^9/L)$ 1.8 24 Jan 2019 $(10^9/L)$ 4.2 24 Jan 2019 $(10^9/L)$ 24 Jan 2019 210 (g/dL) 8 Feb 2019 14.8



2 Aug 2017 Clinical follow-up

Dr. Free2 Will Dana Farber Cancer Insti...

20 Jun 2017 Clinical follow-up

Dr. Free2 Will

Dana Farber Cancer Insti...

14 May 2017

Clinical follow-up

Dr. Free2 Will

Dana Farber Cancer Insti...

8 May 2017

Clinical follow-up

Dr. Free2 Will

Dana Farber Cancer Insti...

View 10 more clinical notes from 2015 - 2017

INAILIE	Gasti Ollitestillai sti Olliai tullioi
Location	Stomach
Clinical status	Remission
Genomics	KIT exon 11 mutation+
Biomarkers	
Disease status	go to disease status
Disease status	Complete response
As of	24 Jan 2019
Rationale	missing
- Treatment	go to medications — go to procedures
Imatinib 400mg tablet	pre-adjuvent 22 Feb 2019 —
Surgery	22 March 2019
Key toxicities	

Diagnosis date	25 Dec 2016	
Recurrence date	N/A	
Mitosis	20 per 50 HPF	
Tumor size	8 cm	
Histological grade	2 (moderately o	lifferentiated)
Clinical stage	IIIA	
Pathological stage	missing	
Lab results		go to lab results
White blood cell	1.8 (10 ⁹ /L)	24 Jan 2019
Neutrophil	4.2 (10 ⁹ /L)	24 Jan 2019
Platelet count	210 (10 ⁹ /L)	24 Jan 2019
Hemoglobin	14.8 (g/dL)	8 Feb 2019


	Sort by most recent ♥	
	+ Search filters	
1	47 previous notes	
ſ	2 Aug 2017	
Н	Clinical follow-up	
Н	Dr. Free2 Will	
	Dana Farber Cancer Insti	
ŀř		$\overline{}$
	20 Jun 2017	
	Clinical follow-up	.
	Dr. Free2 Will	
	Dana Farber Cancer Insti	
ř		
	14 May 2017	
	Clinical follow-up	.
	Dr. Free2 Will	
	Dana Farber Cancer Insti	
ŀř		$\overline{}$
	8 May 2017	
	Clinical follow-up	.
1	Dr. Free2 Will	

Name Gastronitestinal stromal tumor		
Location	Stomach	
Clinical status	Remission	
Genomics	KIT exon 11 mutation	1+
Biomarkers		
– Disease status –		go to disease status
Disease status	Complete response	
As of	24 Jan 2019	
Rationale	missing	
Treatment	go to medications	go to procedures
Imatinib 400mg tablet	pre-adjuvent	22 Feb 2019 —
Surgery		22 March 2019
Key toxicities		

Diagnosis date	25 Dec 2016				
Recurrence date	N/A	N/A			
Mitosis	20 per 50 HPF				
Tumor size	8 cm				
Histological grade	2 (moderately	2 (moderately differentiated)			
Clinical stage	IIIA				
Pathological stage	missing				
Lab results		go to lab results			
White blood cell	1.8 (10 ⁹ /L)	24 Jan 2019			
Neutrophil	4.2 (10 ⁹ /L)	24 Jan 2019			
Platelet count	210 (10 ⁹ /L)	24 Jan 2019			
Hemoglobin	14.8 (g/dL)	8 Feb 2019			

Sort by most recent ▼	
+ Search filters	
47 previous notes	
2 Aug 2017	
Clinical follow-up	
Dr. Free2 Will	
Dana Farber Cancer Insti	
20 Jun 2017	
Clinical follow-up	
Dr. Free2 Will	
Dana Farber Cancer Insti	
14 May 2017	
Clinical follow-up	
Dr. Free2 Will	
Dana Farber Cancer Insti	
8 May 2017	
Clinical follow-up	
Dr. Free2 Will	
Dr. Freez will	

4 ADDITIONAL MEDICATION RESOURCES



Note that MedicationChange is no longer available. It appears that Prior Prescription adopts some of its functionality in MedicaitonRequest.